Oblique Back-illumination Microscopy
Jerome Mertz
June 15, 2012
Oblique Back-illumination Microscopy (OBM)
Breakthrough imaging allows DIC-like images in thick samples
•
•
•
•
600μm field-of-view with 6.5μm resolution
240μm field-of-view with 2.5μm resolution
No labeling or contrast required
Video rate
OBM offers superior imaging and high clinical impact
in a simple, robust, and cost-effective platform
Superior imaging capabilities with high clinical impact
• Exquisite high resolution phase images (DIC-like) of in vivo tissue
morphology
• Simultaneous phase and amplitude microscopy with tissue imaging
depth of 60-100μm
– improves diagnostic imaging in thick tissue
– applications in endoscopy
• Works at video rate with a standard camera
Simple, robust, cost effective, and safe
• Add-on to current microscopes or endomicroscopes, with no moving
parts
• Noninvasive, no tissue labeling required
• Illuminated using LEDs rather than expensive and unsafe lasers
Both research and clinical applications
are possible with OBM
Research
Applications
• $3B US Microscope Market in 2011 with 6%
CAGR through 20151
• Several Established Players: Leica, Carl Zeiss,
Olympus, etc
• 790 Potential Target Labs in US2
Clinical
Applications3
• GI Endoscopy
– > 10 MM Procedures / year
– Colorectal, Gall, Esophageal
• Blood flow analysis in plastic / reconstructive
surgery
– >1MM surgeries per year
• Bladder imaging
1.
2.
3.
Jon Groberg, Dane Leone, CFA, “Danaher: BEC is the key to continued success”,
Macquarie (USA) Equities Research, 16 Aug 2011
Source: http://www.lltechimaging.com/
Source: Mauna Kea Investor Presentation, published June 2011
GI screening offers a compelling opportunity for OBM
Colorectal Screenings
• 3.1 MM colorectal screenings in US
annually
• High percentage of biopsied polyps are
benign
• Strong market opportunity for
technologies that aid in biopsy site
determination
Barrett’s Esophagus
• > 1 MM screenings in US annually
• American Gastroenterological Assoc.
recently increased recommended
screening schedule for high risk patients
• 85% mortality rate for Esophageal
cancer (BE increases cancer risk)
OBM combines high resolution imaging with tissue
depth, wide field-of-view and video capabilities
Technology
OBM
OCT1
Confocal
fluorescence
Endomicroscopy2
Lateral
Resolution (μm)
2.5 / 6.5
3.5
1 - 3.5
Axial Resolution
(μm)
6
1.8
3-8
Imaging Depth
(μm)
0 - 80
100
5 - 100
Field of View
(μm)
240 / 600
1.5 x 1.5 mm
(scanning)
240 / 400
Frame Rate (Hz)
17.5
1
12
(200 optional)
1. Optical Coherence Tomography – data points based on lltech Light-CT
2. Confocal Laser Endomicroscopy – data points based on various CellVizio models
Rigid endoscope market exceeds $500M annually;
Karl Storz is the market leader
Market Share (2010)
Other
17%
Market Size (2010):
• $529M WW, 4% CAGR
Olympus
Medical
10%
Karl Storz
39%
• $176M US, 4% CAGR
• Laparoscopic,
Hysteroscopic uses
Richard
Wolf
16%
Stryker
18%
Source: “Rigid Endoscopes - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to
2017”, Global Data, 31 May 2011
In vivo Imaging Technologies
Technology
Company
Product
Unit Cost
Target Areas
OCT
St. Jude
Medical
Ilumien (OCT +
FFR)
Unknown
Stent Placement, Vulnerable Plaque
ID
OPS
Lekam
Medical Ltd
Cytoscan
Unknown
Microcirculation
(possibly no sales since 2004)
LIF
SpectraScience
wavSTAT
Unknown
Colorectal/esophageal Cancer
Optical
Spectroscopy
Guided
Therapeutics
LuViva
$18,5001
Cervical Cancer
Circulation
Imaging
Novadaq
PinPoint
$75,0004
Lung, Colectomy, Lap Chole, MIS
CLE
Mauna Kea Technologies
(via Leica)
Cellvizio
$160,0002
Barret's, Colorectal, Chole
Multispectral
Imaging
Mela Sciences
MelaFind
$35,0003
Melanoma
1. Thomson Reuters Streetevents, “Edited Transcript: GTHP.OB-Q4 2011 Guided Therapeutics Inc. Earnings
Conference Call”, 29 March 2012, 3:00PM GMT
2. Source: Mauna Kea Investor Presentation, published June 2011
3. Josh Jennings, M.D., Denis Kelleher, Ian Sanderson, Doug Schenkel, “Mela Sciences – Initiating with Outperform
(1)”, Cowen and Company, 23 May 2012
4. Matt Miksic, Sachin Kulharni, Young Li, “ Novadaq: Overweight”, PiperJaffray, Company Note, 16 April 2012